avagacestat

Known as: (2R)-2-(N-((4-Chlorophenyl)sulfonyl)-N-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide, Pentanamide, 2-(((4-chlorophenyl)sulfonyl)((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoro-, (2R)- 
 

Topic mentions per year

Topic mentions per year

2012-2017
012320122017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
INTRODUCTION Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for… (More)
Is this relevant?
2017
2017
γ-Secretase inhibitors (GSIs) are potential therapeutic agents for Alzheimer’s disease (AD); however, trials have proven… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVE To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2012
2012
BACKGROUND γ-Secretase inhibitors (GSIs) are being investigated for their potential to modify the progression of Alzheimer… (More)
Is this relevant?
2012
2012
BACKGROUND AND OBJECTIVES Avagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (A… (More)
Is this relevant?